The use of convalescent plasma to treat emerging infectious diseases

Focus on Ebola virus disease

Anne M. Winkler, Scott A Koepsell

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose of review The purpose of this review is to discuss the use of convalescent plasma for the treatment of emerging infectious diseases, focusing on the recent use for the treatment of Ebola virus disease (EVD). Recent findings Ebola convalescent plasma has been used as a therapy for treatment of EVD during the 2014 West Africa epidemic. Several cases from the United States and Europe have been recently published, in addition to multiple ongoing clinical trials in the United States and West Africa. Even more recently, convalescent plasma has been used for treatment of individuals with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Summary Although the first reports of successful treatment with passive immune therapy date back to the early 1900s, convalescent plasma has materialized as a possible therapy for patients who develop infection from one of the emerging infectious diseases such as EVD or MERS-CoV, although the efficacy of such therapy has yet to be proven in clinical trials.

Original languageEnglish (US)
Pages (from-to)521-526
Number of pages6
JournalCurrent Opinion in Hematology
Volume22
Issue number6
DOIs
StatePublished - 2015

Fingerprint

Ebola Hemorrhagic Fever
Emerging Communicable Diseases
Western Africa
Therapeutics
Coronavirus Infections
Clinical Trials

Keywords

  • Convalescent plasma
  • Ebola
  • Ebola virus disease
  • Middle east respiratory syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

The use of convalescent plasma to treat emerging infectious diseases : Focus on Ebola virus disease. / Winkler, Anne M.; Koepsell, Scott A.

In: Current Opinion in Hematology, Vol. 22, No. 6, 2015, p. 521-526.

Research output: Contribution to journalArticle

@article{b68e108afd08404f97649126a8db6245,
title = "The use of convalescent plasma to treat emerging infectious diseases: Focus on Ebola virus disease",
abstract = "Purpose of review The purpose of this review is to discuss the use of convalescent plasma for the treatment of emerging infectious diseases, focusing on the recent use for the treatment of Ebola virus disease (EVD). Recent findings Ebola convalescent plasma has been used as a therapy for treatment of EVD during the 2014 West Africa epidemic. Several cases from the United States and Europe have been recently published, in addition to multiple ongoing clinical trials in the United States and West Africa. Even more recently, convalescent plasma has been used for treatment of individuals with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Summary Although the first reports of successful treatment with passive immune therapy date back to the early 1900s, convalescent plasma has materialized as a possible therapy for patients who develop infection from one of the emerging infectious diseases such as EVD or MERS-CoV, although the efficacy of such therapy has yet to be proven in clinical trials.",
keywords = "Convalescent plasma, Ebola, Ebola virus disease, Middle east respiratory syndrome",
author = "Winkler, {Anne M.} and Koepsell, {Scott A}",
year = "2015",
doi = "10.1097/MOH.0000000000000191",
language = "English (US)",
volume = "22",
pages = "521--526",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The use of convalescent plasma to treat emerging infectious diseases

T2 - Focus on Ebola virus disease

AU - Winkler, Anne M.

AU - Koepsell, Scott A

PY - 2015

Y1 - 2015

N2 - Purpose of review The purpose of this review is to discuss the use of convalescent plasma for the treatment of emerging infectious diseases, focusing on the recent use for the treatment of Ebola virus disease (EVD). Recent findings Ebola convalescent plasma has been used as a therapy for treatment of EVD during the 2014 West Africa epidemic. Several cases from the United States and Europe have been recently published, in addition to multiple ongoing clinical trials in the United States and West Africa. Even more recently, convalescent plasma has been used for treatment of individuals with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Summary Although the first reports of successful treatment with passive immune therapy date back to the early 1900s, convalescent plasma has materialized as a possible therapy for patients who develop infection from one of the emerging infectious diseases such as EVD or MERS-CoV, although the efficacy of such therapy has yet to be proven in clinical trials.

AB - Purpose of review The purpose of this review is to discuss the use of convalescent plasma for the treatment of emerging infectious diseases, focusing on the recent use for the treatment of Ebola virus disease (EVD). Recent findings Ebola convalescent plasma has been used as a therapy for treatment of EVD during the 2014 West Africa epidemic. Several cases from the United States and Europe have been recently published, in addition to multiple ongoing clinical trials in the United States and West Africa. Even more recently, convalescent plasma has been used for treatment of individuals with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Summary Although the first reports of successful treatment with passive immune therapy date back to the early 1900s, convalescent plasma has materialized as a possible therapy for patients who develop infection from one of the emerging infectious diseases such as EVD or MERS-CoV, although the efficacy of such therapy has yet to be proven in clinical trials.

KW - Convalescent plasma

KW - Ebola

KW - Ebola virus disease

KW - Middle east respiratory syndrome

UR - http://www.scopus.com/inward/record.url?scp=84944074721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944074721&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000191

DO - 10.1097/MOH.0000000000000191

M3 - Article

VL - 22

SP - 521

EP - 526

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 6

ER -